NovaBridge Biosciences (NBP) EBIAT (2019 - 2025)
NovaBridge Biosciences (NBP) reported EBIAT of -$103.8 million for Q4 2025, down 1057.41% year-over-year from $10.8 million in Q4 2024, and down 530.15% on a QoQ basis from $24.1 million in Q3 2025.
NovaBridge Biosciences (NBP) has 5 years of EBIAT data on file, last reported at -$103.8 million in Q4 2025.
- Quarterly EBIAT fell 1057.41% year-over-year to -$103.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 16198.89% YoY) and the FY2025 annual result came in at -$88.3 million, down 497.39% from the prior year.
- EBIAT declined to -$103.8 million in Q4 2025 per NBP's latest filing, from $24.1 million in the prior quarter.
- Across five years, EBIAT topped out at $25.4 million in Q2 2024 and bottomed at -$103.8 million in Q4 2025.
- The 3-year median for EBIAT is -$5.5 million (2025), against an average of -$13.2 million.
- Peak annual rise in EBIAT reached 217.79% in 2025, while the deepest fall reached 1057.41% in 2025.
- Tracing NBP's EBIAT over 3 years: stood at -$36.9 million in 2023, then jumped by 129.38% to $10.8 million in 2024, then sank by 1057.41% to -$103.8 million in 2025.
- Per Business Quant, the three latest NBP EBIAT figures stand at -$103.8 million (Q4 2025), $24.1 million (Q3 2025), and -$5.5 million (Q2 2025).
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -103.82 Mn |
| Sep 30, 2025 | 24.14 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 25.42 Mn |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | -36.91 Mn |
| Sep 30, 2023 | 8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | -12.97 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -364.40 Mn |
| Sep 30, 2019 | -35.10 Mn |